Table 1. Clinical and descriptive characteristics of mild vs. moderate AS patients.
| AVAI ≥0.58 cm2/m2 n = 180 | AVAI <0.58 cm2/m2 n = 194 | p-value | |
| Age, yrs. | 66.1±9.9 | 66.3±9.3 | 0.81 |
| Gender (male/female), n | 109/73 | 130/72 | 0.37 |
| Body surface area, m2 | 1.88±0.21 | 1.94±0.19 | 0.002 |
| Treatment vs. Placebo,% | 53.3/46.7 | 48.02/51.98 | 0.30 |
| Biochemical analyses | |||
| Fibulin-1, µg/mL | 67.5±19.7 | 71.2±16.7 | 0.045 |
| NT-proBNP, pg/mL | 138.9 (30.0–745.8) | 179.5 (27.2–1414.6) | 0.018 |
| suPAR, ng/mL | 3.6±1.11 | 3.7±1.24 | 0.44 |
| C-reactive protein, mg/L | 0.21 (0.03–1.27) | 0.19 (0.03–0.96) | 0.37 |
| Serum creatinine, mg/dL | 95.2±15.7 | 97.2±15.5 | 0.20 |
| Aspartate aminotransferase, U/L | 17.7±6.7 | 16.8±4.02 | 0.12 |
| γ-glutamyl transferase, U/L | 24.9±25.5 | 23.7±20.9 | 0.61 |
| Cardiovascular measurements | |||
| Systolic blood pressure, mm Hg | 143.2±19.3 | 144.9±20.0 | 0.41 |
| Diastolic blood pressure, mm Hg | 81.5±9.3 | 82.2±9.4 | 0.46 |
| Ejection fraction,% | 65.5±8.7 | 64.7±8.4 | 0.34 |
| Fractional shortening,% | 36.7±6.7 | 35.9±6.3 | 0.28 |
| Left ventricular mass index, g/m2 | 95.5±26.8 | 100.6±28.6 | 0.071 |
| Aortic valve area index, cm2/m2 | 0.75±0.142 | 0.47±0.074 | <0.0001 |
| Relative wall thickness | 0.32±0.07 | 0.34±0.08 | 0.002 |
Values are arithmetic mean ± SD, geometric mean (5th and 95th percentiles) or the number of participants indicated as percentage. Left ventricular mass and Aortic valve area were indexed by Body surface area.